Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis

Experimental and Therapeutic Medicine

Volumn 7, Issue 6, 2014, Pages 1663-1670

  Yang, Min ^a   Li, Min ^a   He, Wei ^a   Wang, Bin ^a   Gu, Yong ^b  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Calcineurin inhibitors; Cyclosporine; Lupus nephritis; Meta analysis; Tacrolimus

Indexed keywords

ALBUMIN; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; TACROLIMUS;

ARTICLE; CLEARANCE; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; INFORMATION RETRIEVAL; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS; OUTCOME ASSESSMENT; PATHOLOGY; PROTEINURIA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK FACTOR; SLEDAI; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84898416735     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1669     Document Type: Article

References (38)

1. Cervera R, Khamashta MA, Font J, et al; The European Working Party on Systemic Lupus Erythematosus: Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine (Baltimore) 72: 113-124, 1993.
2. Mok CC and Tang SS: Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 117: 791-795, 2004.
3. Austin HA III, Klippel JH, Balow JE, et al: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614-619, 1986.
4. Carette S, Klippel JH, Decker JL, et al: Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med 99: 1-8, 1983.
5. Boumpas DT, Austin HA III, Vaughn EM, et al: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992.
6. Mok CC, Wong RW and Lai KN: Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 62: 799-804, 2003.
7. Bhat P and Radhakrishnan J: B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int 73: 261-268, 2008.
8. Sommerer C, Giese T, Meuer S and Zeier M: New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients. Saudi J Kidney Dis Transpl 21: 1030-1037, 2010.
9. Chen W, Tang X, Liu Q, et al: Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 57: 235-244, 2011.
10. Wang S, Li X, Qu L, et al: Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus 21: 1025-1035, 2012.
11. Li X, Ren H, Zhang Q, et al: Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 27: 1467-1472, 2012.
12. Szeto CC, Kwan BC, Lai FM, et al: Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 47: 1678-1681, 2008.
13. Zavada J, Pesickova S, Rysava R, et al: Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 19: 1281-1289, 2010.
14. Austin HA III, Illei GG, Braun MJ and Balow JE: Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20: 901-911, 2009.
15. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12, 1996.
16. Moher D, Pham B, Jones A, et al: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613, 1998.
17. Kjaergard LL, Villumsen J and Gluud C: Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135: 982-989, 2001.
18. Oremus M, Oremus C, Hall GB and McKinnon MC: Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales. BMJ Open 2: e001368, 2012.
19. Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558, 2002.
20. Miyasaka N, Kawai S and Hashimoto H: Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 19: 606-615, 2009.
21. Yap DY, Yu X, Chen XM, et al: Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) 17: 352-357, 2012.
22. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT and Li LS: Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19: 2001-2010, 2008.
23. Valeri A, Radhakrishnan J, Estes D, et al: Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 42: 71-78, 1994.
24. Mok CC, Ho CT, Siu YP, et al: Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38: 256-264, 2001.
25. Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L and Ajzen H: A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 3: 107-112, 1994.
26. Belmont HM, Storch M, Buyon J and Abramson S: New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 4: 104-108, 1995.
27. Dooley MA and Ginzler EM: Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum Dis Clin North Am 32: 91-102, 2006.
28. Scott LJ, McKeage K, Keam SJ and Plosker GL: Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63: 1247-1297, 2003.
29. Lee YH, Lee HS, Choi SJ, Dai Ji J and Song GG: Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus 20: 636-640, 2011.
30. Deng J, Huo D, Wu Q, Yang Z and Liao Y: A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med 227: 281-288, 2012.
31. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C and Pauker SG: Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 14: 108-117, 1994.
32. Jones T and Evans D: Conducting a systematic review. Aust Crit Care 13: 66-71, 2000.
33. Flather MD, Farkouh ME, Pogue JM and Yusuf S: Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials 18: 568-579; discussion 661-666, 1997.
34. Alarcón GS, Friedman AW, Straaton KV, et al: Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: Nature vs. Nurture. Lupus 8: 197-209, 1999.
35. Cooper GS, Parks CG, Treadwell EL, et al: Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 11: 161-167, 2002.
36. Moroni G, Doria A and Ponticelli C: Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 24: 15-20, 2009.
37. Favre H, Miescher PA, Huang YP, Chatelanat F and Mihatsch MJ: Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 9 (Suppl 1): 57-60, 1989.
38. Chen W, Liu Q, Chen W, et al: Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 21: 944-952, 2012.